Experimental pancreatic cancer combo trial halted early
NCT ID NCT04643405
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested an experimental drug called APG-1387 combined with standard chemotherapy (gemcitabine and nab-paclitaxel) in people with advanced pancreatic cancer. The goal was to find the safest dose and see if the combination could shrink tumors. However, the trial was terminated early after enrolling only 21 participants, so the full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- APG-1387 (an experimental drug) plus gemcitabine and nab-paclitaxel (standard chemotherapy)
- What this could lead to
- If successful, this combination could offer a new treatment option for advanced pancreatic cancer patients who have failed standard therapy.
- What could go wrong
- The trial was terminated early with only 21 participants, so results are limited. The drug combination may cause significant side effects, and it is unclear if it improves survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Pan-RAS inhibitor outsmart pancreatic cancer?
- Can a targeted antibody slow advanced pancreatic cancer?
- New Antibody-Drug combo takes on Hard-to-Treat pancreatic cancer
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- New drug targets Hard-to-Treat pancreatic cancer by hitting a common mutation
- Drug cocktail aims to stall pancreatic cancer in patients who have run out of options